[
  {
    "ts": null,
    "headline": "Health Care Down on Defensive Bias -- Health Care Roundup",
    "summary": "Health-care companies fell, but not by as much as the broad market, amid a rotation back into the out-of-favor defensive sector. Walgreen Boots Alliance surged after the drug-store chain's...",
    "url": "https://finnhub.io/api/news?id=35ef89d72bfbb511e8bee6ededc046e72a9caad2597e46105dc8f55e5ebea384",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736530878,
      "headline": "Health Care Down on Defensive Bias -- Health Care Roundup",
      "id": 132372849,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Health-care companies fell, but not by as much as the broad market, amid a rotation back into the out-of-favor defensive sector. Walgreen Boots Alliance surged after the drug-store chain's...",
      "url": "https://finnhub.io/api/news?id=35ef89d72bfbb511e8bee6ededc046e72a9caad2597e46105dc8f55e5ebea384"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Constellation Brands, Allstate, Delta Air Lines, and More",
    "summary": "U.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt.",
    "url": "https://finnhub.io/api/news?id=393e3061b049d30865e1bda4e246261751752b189fc894fc4a129840bcc0e9a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736528656,
      "headline": "Top Stock Movers Now: Constellation Brands, Allstate, Delta Air Lines, and More",
      "id": 132367124,
      "image": "https://www.investopedia.com/thmb/7DvjaKyuNQTQa5xqzRQjR6COzcs=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1498503625-0af0a0d329744dbb9f16c49beb86ab03.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "U.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt.",
      "url": "https://finnhub.io/api/news?id=393e3061b049d30865e1bda4e246261751752b189fc894fc4a129840bcc0e9a6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug",
    "summary": "AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics.",
    "url": "https://finnhub.io/api/news?id=43ba163211d64a656d44283585bebb436a9ea3c37a231863ed28b007b27a6942",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736525424,
      "headline": "AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug",
      "id": 132365551,
      "image": "https://www.investopedia.com/thmb/EqPonjHm7Qn8xFYW-ALIletdmvw=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2184833968-7c355e309d3c47f5afb4848e49053a41.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics.",
      "url": "https://finnhub.io/api/news?id=43ba163211d64a656d44283585bebb436a9ea3c37a231863ed28b007b27a6942"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug",
    "summary": "AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .",
    "url": "https://finnhub.io/api/news?id=97a6b4045918c6813d8779a58a2bc8da0119392a70246a21b0aed39a463b96c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736518560,
      "headline": "AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug",
      "id": 132365552,
      "image": "",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .",
      "url": "https://finnhub.io/api/news?id=97a6b4045918c6813d8779a58a2bc8da0119392a70246a21b0aed39a463b96c5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets",
    "summary": "Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.",
    "url": "https://finnhub.io/api/news?id=c07693953a57098badbae424aa4662c47581d1f9f7e396d22552086923970693",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736509380,
      "headline": "Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets",
      "id": 132365554,
      "image": "https://imgproxy.divecdn.com/EK5xKj0ydykvmwFmBqsauREtdhrHAUsAiyI6JgDkO1s/g:nowe:0:0/c:1207:682/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.",
      "url": "https://finnhub.io/api/news?id=c07693953a57098badbae424aa4662c47581d1f9f7e396d22552086923970693"
    }
  },
  {
    "ts": null,
    "headline": "MoneyShow's Best Investment Ideas For 2025: Part 2",
    "summary": "MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, Agnico Eagle, AbbVie, Morgan Stanley and Nomura, among others.",
    "url": "https://finnhub.io/api/news?id=f8833de5b7d75b31c438f534fdb7d227d765703618fc9712fd3d6799b39215b3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736501400,
      "headline": "MoneyShow's Best Investment Ideas For 2025: Part 2",
      "id": 132363465,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, Agnico Eagle, AbbVie, Morgan Stanley and Nomura, among others.",
      "url": "https://finnhub.io/api/news?id=f8833de5b7d75b31c438f534fdb7d227d765703618fc9712fd3d6799b39215b3"
    }
  },
  {
    "ts": null,
    "headline": "DLN: Dividend ETF Leading Its Competitors",
    "summary": "WisdomTree U.S. LargeCap Dividend Fund ETF provides value with 300 dividend stocks. Read why DLN is better for total return, despite lower yields and growth.",
    "url": "https://finnhub.io/api/news?id=9cd4e679d4cd2800d68ea88d78682a5d4a853aa9ce1e4eacfbc8e10e73525029",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736496000,
      "headline": "DLN: Dividend ETF Leading Its Competitors",
      "id": 132362585,
      "image": "https://media.gettyimages.com/id/sb10064568u-001/photo/cyclists-racing-side-view.jpg?b=1&s=612x612&w=0&k=20&c=mEo64eDNGUpi9QAEQgRUluiT__WYX8NGoEt6t8D26hw=",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "WisdomTree U.S. LargeCap Dividend Fund ETF provides value with 300 dividend stocks. Read why DLN is better for total return, despite lower yields and growth.",
      "url": "https://finnhub.io/api/news?id=9cd4e679d4cd2800d68ea88d78682a5d4a853aa9ce1e4eacfbc8e10e73525029"
    }
  },
  {
    "ts": null,
    "headline": "NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration",
    "summary": "NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.",
    "url": "https://finnhub.io/api/news?id=a9f3641c501e6bded39b760bceadb26505bf805937725f8186845afbf298946d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736483843,
      "headline": "NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration",
      "id": 132359861,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91156685/image_91156685.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.",
      "url": "https://finnhub.io/api/news?id=a9f3641c501e6bded39b760bceadb26505bf805937725f8186845afbf298946d"
    }
  }
]